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An index of agonism is described which can be used to quantify agonist receptor 
selectivity, bias, cell-based agonism and the effects of receptor mutation on signaling . 
The parameter is derived from agonist concentration-response curves and is comprised 
of the maximal response to the agonist (max) and the EC50 (concentration of agonist 
producing half maximal response) in the form of Log(max/EC50).  This parameter is 
derived from equations describing agonists as positive allosteric facilitators of receptor-
signaling protein interaction. A similar index is also derived to quantify the potentiating 
effects of positive allosteric modulators which can be used to quantify in situ PAM 
activity in vivo. These indices lend themselves to statistical analysis and are system 
independent in that the effects of the system processing of agonist response and 
differences in assay sensitivity and receptor expression are cancelled. The various 




This article has not been copyedited and formatted. The final version may differ from this version.

















A critical component of the lead optimization process in new drug discovery for  
agonists and allosteric modulators is the determination of relative measures of activity 
that are not specifically linked only to the assays in which they are measured, i.e. they 
are system-independent measures of activity. For full agonists, system independent 
measures of activity are achieved through relative potency ratios (ratios of EC50 values 
where EC50 refers to the concentration of agonist producing 50% maximal response). 
However, this scale devolves into a non-linear scale when comparing full and partial 
agonists so it cannot be used for the comparison of these types of agonists. In this 
paper, agonism is developed as a positive allosteric modulation of the natural receptor-
signaling protein interaction and the resulting scale is presented as a system 
independent measure of the relative receptor activation for any set of agonists (full or 
partial). Separately, the same approach is applied to the assessment of the relative 
activity of any set of allosteric modulators positive (PAMs) or negative (NAMs). While 
the activity of NAMs can be quantified with standard methods for antagonists, the 
affinity of PAMs is uniquely dependent on the co-binding agonist and thus require 
special methods to assess.  This new scale may be particularly useful in that it can be 
used to furnish system-independent measures of PAM activity in vivo for advancement 
of candidate molecules. 
Receptor-Signaling Protein Interaction  
The discovery of constitutive seven transmembrane receptor (7TMR) activity 
(Costa and Herz, 1989) and subsequent recasting of the ternary complex model for 
receptors to the extended ternary complex model (Samama et al, 1993) reveals that 
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agonists can be considered simply as positive allosteric modulators of an already 
ongoing spontaneous association between the receptor and the signaling protein 
(Kenakin, 2015). In accordance with the standard functional allosteric model for 
receptors (Kenakin, 2005; Ehlert, 2005; Price et al, 2005) such modulators (in this case 
agonists) can change the affinity of the receptor for the signaling protein (through a co-
operativity term ) and the efficacy of the receptor-signaling protein complex for 
production of cellular response (through a co-operativity term ). In terms of binding, the 
relevant protein species can be described within the context of the standard Stockton-
Ehlert allosteric binding model (Stockton et al,1983; Ehlert, 1989) whereby the agonist 
(denoted A)  and signaling protein (denoted G) bind to separate but interactive sites on 
the receptor. Thus both A and G interact with the receptor with equilibrium association 
constants K’a and Kg respectively: 
  …[1] 
This binding model is then placed as the receptor species producing unit for the 
Black/Leff operational model of agonism (Black and Leff, 1983) to yield the functional 
allosteric model. An ‘allosteric vector’ can be described to denote the direction of 
modulation (Kenakin and Miller, 2010) which in this case has the binding of a ligand to 
the receptor directing the modification of the interaction between the receptor and a 
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signaling protein within the cytosol; this vector constitutes agonism. It should be noted 
that G protein coupled receptors have been described as allosteric proteins in the 
literature in early mathematical models (see Karlin, 1967; Thron, 1973). The standard 
functional allosteric model for a cytosol-directed vector can be used to show that ratios 
of the maximal response (max) and EC50 (concentration of agonist producing half 
maximal response) from agonist concentration-response curves for a set of agonists (to 
furnish Log(max/EC50) values)  creates a system independent scale of agonism that 
can be used to quantify selectivity- see Appendix 1 for derivation.  This same conclusion 
can be reached through derivation of the term within the Black/Leff operational model as 
well- see Kenakin (2015) and Appendix 2. 
Historically, the relative activity of agonists has been quantified through potency 
ratios (for example differences in the negative logarithm of EC50 values denoted as 
pEC50). For full agonists pEC50 values are constant over all ranges of system 
sensitivity (as long as both agonists produce full system response, i.e. are full agonists). 
However, this relationship breaks down when one or both of the agonists becomes a 
partial agonist because the impact of tissue sensitivity on the potency of full and partial 
agonists is different. Specifically, reductions in receptor density for full agonists produce 
defined dextral displacement of concentration-response curves in contrast to the effect 
produced on curves for partial agonists which essentially do not change location along 
the concentration axis but rather show depressed maxima (see Fig 1A). This produces 
distinctly non-linear changes in the relative pEC50 values of an agonist when it 
expresses partial agonism in systems of low sensitivity- see curvature in the relationship 
between pEC50 and receptor density shown in Fig 1B. This non-linearity makes pEC50 
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values dependent on tissue sensitivity and thus not useful as a system-independent 
index of relative agonist activity. For dose response curves with Hill coefficients not 
significantly different from unity normalization of agonist activity through inclusion of the 
maximal response (in the form of Log(max/EC50) values) corrects this dependence on 
tissue sensitivity and yields a truly system-independent scale of agonism (see Fig 1); 
this effect is shown with experimental data in Fig 2 for the -adrenoceptor partial agonist 
prenalterol and full agonist isoproterenol. As shown in Fig 2, the pEC50 values produce 
a distinct curvature with varying tissues while Log(max/EC50) values remain constant 
through a range of tissue conditions. 
There are three important points to consider when discussing Log(max/EC50) 
values; the first is the fact that calculation of max/EC50 reduces agonism to a single 
number. This is useful from the point of view of allowing statistical analyses (i.e. as in 
the analysis of signaling bias, Kenakin et al, 2012). The various formulae to do this are 
described in Appendix 3 with the key parameter to enable the calculations being an 
estimate of pooled variance (Kenakin et al, 2012).  Thus, estimates of the agonism 
produced by any molecule can be made with mean Log(max/EC50) values + 95% c.l., 
comparison of the relative base agonist activity in any one system can be made with 
Log(max/EC50) values + 95% confidence limits (c.l.) and finally, comparisons of 
selectivity, bias and the effects of mutation made through Log(max/EC50) + 95% c.l. 
estimates with simple adjustment of formulae based on the pooled variance- see 
Appendix 3.  
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The second point is that the comparison of Log(max/EC50) values between 
agonists in a single functional system to produce Log(max/EC50) allows the system 
independent scaling of agonism within a given functional system. When this is done the 
agonism of a test compound is compared to a reference agonist and system effects are 
cancelled, i.e. the sensitivity of the functional system is not an issue and the 
Log(max/EC50) reflects molecular efficacy and affinity in a system independent manner 
within a given assay. The third point involves the cross comparison of different response 
systems whether they be signaling pathways in the cell or different receptors. Once the 
power of a test agonist is scaled to the same reference agonist in two systems, then 
Log(max/EC50) values cancel cross system effects (including differences in assay 
sensitivity) and become independent measures of the power of the agonist activation 
across the two systems. This can be in terms of different receptors (receptor selectivity), 
different signaling pathways (biased signaling), cell-based agonist selectivity, or 
measures of the impact of receptor mutation on a given agonist activity. It is worth 
considering these settings as they are fundamental pharmacological procedures applied 
to the quantitative measurement of agonist effect. As a pre-requisite it is useful to 
consider some operational features of the analysis. 
Practical Use of the Log(max/EC50)  
It is important to note that the maximal response for agonism must be expressed 
as a fraction of the maximal window available in the assay to express agonism and not 
simply as the maximal response to the most efficacious agonist in the assay. For 
example, if direct activation of adenylate cyclase with forskolin in a given functional 
assay produces a maximal elevation of cyclic AMP greater than the most efficacious 
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agonist in the assay, then the maximal response to the agonist must be expressed as a 
fraction of the maximal effect of forskolin. In addition, the derivation given in Appendix 1 
assumes that the Hill coefficient of the agonist concentration response curves are not 
significantly different from unity. In the comparison of the Black/Leff operational model 
scale of Log(/KA) to Log(max/EC50) values this is an explicit requirement to equate 
the two values (Appendix 2). In some instances in experimental pharmacology this is 
not the case therefore it is useful to explore the effects of slopes differing from unity on 
the immutability of the Log(max/EC50) scale with receptor density and tissue 
sensitivity. Specifically, the comparison is made between a curve fit to the Hill equation 
of Response = [A]n max/([A]n + EC50n) where n=1 and n≠1.Then comparisons of 
different Log(max/EC50) values can be made through simulation whereby the actual 
values of Log(max/EC50) values for concentration response curves of different slopes 
can be compared to the true values of Log(/KA); this yields an error term  where: 
  =  Log(max/EC50)   -  Log(/KA)  …[2] 
Fig 3 shows a simulation surface of the dependence of  on slope and maximal 
response of the agonist concentration response curves. It can be seen from this figure 
that slopes > 1 provide Log(max/EC50) values that depend only slightly on slope (as 
indicated by the small deviation with agonist maxima). In fact, the main region of 
deviation occurs with agonist concentration-response curves of low maximal response 
and slopes significantly less than unity. This should be considered as a caution to the 
use of Log(max/EC50) values for low efficacy agonists (maximal responses < 35%) 
demonstrating concentration response curves with slopes significantly lower than 0.5. 
This article has not been copyedited and formatted. The final version may differ from this version.
















Table 1 shows the sequential procedures required to apply the Log(max/EC50) 
scale for quantification of selectivity for different receptors, signaling pathways, cell 
types and receptor sequence.  
Log(max/EC50) Quantification of Receptor Selectivity 
Historically, receptor selectivity has been expressed as the ratio of agonist potencies 
and for full agonists this yields useful and system independent measures. However, as 
discussed above, the use of maximal responses extends this scale to all agonists, 
partial and full and provides a more inclusive scale.  Table 2 shows data describing 
concentration-response curves for four muscarinic agonists on M1 and M4 receptors 
(CHO cell GTPS binding) from Watt et al, 2011. Selectivity can be calculated through 
conventional potency values (EC50) or through Log(max/EC50) and in the case of 
Talsididine, different outcomes illustrate the effect of ignoring differences in maximal 
response. In cases where partial agonism is produced, EC50 values over-estimate the 
agonism of the ligand because full agonism is assumed in the calculation. The first step 
is to cancel the effect of the sensitivity of each assay by comparing agonism to a 
reference compound; in this case, acetylcholine is the reference. Considering pEC50 
values first, talsididine is 0.032-fold as active as acetylcholine on M1 receptors and 
0.066-fold as active as acetylcholine on M4 receptors; this leads to an overall selectivity 
of talsididine of 2.1 for M4 receptors (talsididine is relatively more active on M4 than M1 
receptors ). Use of Log(max/EC50) values leads to a different conclusion;  talsididine is 
0.022-fold as active on M1 receptors and 0.016-fold as active on M4 receptors ; this 
leads to an overall selectivity of 1.38-fold for M1 receptors (non-selective). This is in 
keeping with the lower maximal response of talsididine for M4 receptors (21.6%) 
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indicating a lower activity for that receptor subtype. In general pEC50 values assume a 
maximal response for M4 receptors thereby over-estimating M4 activity and erroneously 
classifying talsididine as M4-selective. Fig 4 shows the selectivity of the four agonists in 
these recombinant functional systems where it can be seen that as the maximal 
responses to the agonists diminish, the disparity between Log(max/EC50) and 
pEC50 increases.  
General tissue selectivity of agonists also can be quantified; Fig 5 shows the relative 
activity of 8 muscarinic agonists, compared to that of acetylcholine, in guinea pig 
bladder and ileum. Relative selectivity is calculated through Log(max/EC50) values 
and relative agonist potency ratios as pEC50 values. In this calculation, the value for 
each agonist within a given tissue is compared to that of acetylcholine through 
Log(max/EC50) or pEC50 values and then the selectivity between the tissues 
assessed through differences of these values in these two tissues to yield 
Log(max/EC50) or pEC50 values for tissue selectivity (to cancel differences in 
tissue sensitivity between the assays). The result is a measure of how well the agonists 
activate the muscarinic receptors of guinea pig bladder and ileum. Tissue selective 
differences might be seen with varying mixtures of receptor type in each tissue or a cell 
type effect on biased agonism (Kenakin, 2016); the analysis makes no assumptions as 
to the nature of the differences in potency and functions only as an operational measure 
of observed selectivity.  It can be seen that, as expected, estimates are identical when 
both agonists produce full agonism. However, in drug discovery programs where new 
test molecules of low intrinsic activity are compared to powerful standard agonists, this 
scale becomes important.  This is illustrated by the deviations in values in Fig 5 when 
This article has not been copyedited and formatted. The final version may differ from this version.
















one of the agonists is a partial agonist in either tissue (see far right column of table 
showing relative maxima and compare differences between Log(max/EC50) and 
pEC50).   
Log(max/EC50) Quantification of Signaling Bias 
Just as extracellular agonist selectivity can be quantified with this scale, so too 
can intracellular selectivity (agonist bias). This occurs when a given agonist that 
interacts with a pleiotropically coupled receptor selectively activates one or more of the 
signaling cascades at the expense of others, i.e. it biases the stimulus and does not 
distribute activation evenly amongst the available pathways. This is predicted to be the 
result of the stabilization of different receptor active states by different agonists (Kenakin 
and Morgan, 1989; Kenakin, 1995) and, irrespective of mechanism,  is a widespread 
phenomenon in pharmacology studied by numerous research groups and given a 
variety of names (i.e. ‘stimulus trafficking’, (Kenakin, 1995); ‘biased signaling’ (Jarpe et 
al, 1998); ‘functional selectivity’ (Lawler et al, 1999); ‘collateral efficacy’ (Kenakin, 2005);  
‘functional dissociation’ (Whistler and van Zastrow, 1999); ‘biased inhibition’ (Kudlacek 
et al, 2002); ‘differential engagement’ (Manning, 2002)). Insofar as signaling bias may 
be a therapeutically exploitable favorable agonist property, it is useful to have a 
quantitative scale to guide medicinal chemists in efforts to optimize this effect.  
A theoretically optimal scale for this utilizes Log(/KA) values (Kenakin et al, 
2012; Kenakin and Christopoulos, 2013) and just as Log(max/EC50) values can be 
useful surrogates for agonist selectivity, they can also function as the same for signaling 
bias. Thus, when the slopes of the concentration response curves to the agonists are 
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>0.5 or maximal responses > 35%, Log(max/EC50) values can provide convenient 
and rapid assessment of signaling bias. Just as for receptor selectivity, Log(max/EC50) 
values are calculated for each agonist for two signaling pathways and then compared 
through Log(max/EC50) values using a reference agonist in each (the reference 
agonist must be the same for both pathways). This cancels the relative effects of assay 
sensitivity in each assay. This is extremely important as signaling assays such as 
effects on second messengers (i.e. cyclic AMP) are highly coupled and much more 
sensitive than assays quantifying -arrestin complementation. After this, cross pathway 
comparison can be done through comparison of Log(max/EC50) values to yield values 
of Log(max/EC50). The bias is then calculated as the antilog of Log(max/EC50) 
values. It should be noted that the bias is a vector that can be expressed in two 
directions. For example, a bias for two agonists A and B showing that agonist A favors 
the cAMP system (over-arrestin) by a factor of 5 can also be expressed as agonist A 
having a bias away from -arrestin of 0.2. In general, when bias values are reported, 
this vector orientation must always be denoted.  
Fig 6 shows the bias of 5 opioid receptor agonists, compared to that of salvinorin 
A, for -opioid receptor inhibition of cAMP production and -arrestin signaling pathways 
(White et al, 2013). Just as with receptor selectivity, it can be seen that bias estimates 
differ when one of the agonists produces partial maximal response and simple EC50 
values (in the form of pEC50) vs consideration of maxima (in the form of 
Log(max/EC50) estimates are used. In general, bias is under-estimated if only EC50 
values are utilized.  
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Assessment of Cell-Type Specificity 
A well known observation in pharmacology is the imposition of cell type effects 
on receptor selectivity. For example, expression of the same receptor in different host 
cell types can produce differences in the relative potency ratios of agonists (i.e. 
calcitonin, Christmansson et al, 1994; Watson et al, 2000). While this is incompatible 
with a monotonic receptor coupling scheme for agonists in cells, it can occur if agonists 
produce biased signaling at the receptor and the difference host cell types emphasize 
the heterogenous signals in different ways (Kenakin, 2016); in these cases  
Log(max/EC50) values can be used to identify cell type specificity.Specifically, bias 
plots, where the response to an agonist in one cell type is expressed  as a function of 
the response in another cell type, can furnish visual data to indicate where an agonist 
produces a unique response in a given cell type over other agonists. For example, Fig 7 
shows label free responses to muscarinic agonists in HT-29 and SF268 cells (Deng et 
al, 2013). A linear relationship would not necessarily be expected as different cell types 
may have differing receptor expression levels and efficiency of receptor coupling but if 
the agonists produce a uniform receptor active state, then a concordance (i.e. no 
deviations in the relationship for any one agonist) in this bias plot would be expected for 
all agonists tested. However, as seen in Fig 7, while most of the agonists followed a 
fairly uniform pattern, bethanechol shows a distinctly different bias being uniquely more 
active in SF268 cells than HT-29 cells (as compared to the other agonists). This 
difference can be quantified and statistically estimated through Log(max/EC50) 
values. For example, the data shown in theTable with Fig 7, shows that bethanechol is 
7.86-fold biased toward producing responses in SF268 cells vs HT-29 cells.  If, in the 
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example shown in Fig 7, the mean cell bias toward response in SF268 cells for 
acetylcholine, methacholine, carbachol and Oxo-M is 1.7, bethanechol produces a 
7.86/1.7= 4.5-fold selective bias toward SF268 cells compared to these other agonists. 
This type of analysis might be applied to the testing of ligands in healthy cells those 
from disease models (or tumor vs normal cells) to identify unique cell-based activity for 
therapeutic applications.  
Assessment of Receptor Mutation 
In the study of the effects of receptor mutations on agonist function and 
functional signaling, important considerations are differences due to variations in 
receptor expression. The application of Log(max/EC50) values negates this problem 
through comparison of effects to a common standard for both the wild type and mutated 
receptor. Just as with the assessment of signaling bias, the internal comparison of 
agonist function to a common reference agonist for both the wild type and mutated 
receptor cancels any effective differences in the disposition of the two types of receptor 
protein by the cell. Once the relative agonism of two agonists is quantified for each 
receptor species (wild type vs mutation), then comparisons between them can be made 
that will be corrected for efficiency of transduction and expression with 
Log(max/EC50) values. One possible difference from the process used to assess 
signaling bias is in the choice of reference agonist. Specifically, when quantifying 
signaling bias, usually the test agonist is compared to the natural agonist to yield a 
measure of predicted differences in signaling with the synthetic agonist (as opposed to 
natural signaling). While natural signaling is sometimes referred to as ‘unbiased 
signaling’ this is a misnomer since the natural agonist will be biased according to the 
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physiological needs of the organ; therefore, what is measured as ‘bias’ for the synthetic 
ligand is simply a difference from the bias of the natural ligand. In contrast, when 
exploring the effects of mutation on receptor function, the aim often is to assess the 
effects of the mutation on the natural wild type receptor interacting with the natural 
agonist. Under these circumstances, a synthetic ligand is chosen as the reference 
agonist (to cancel systems effects) and the induced bias on the natural ligand is thus 
measured as an assessment of the effects of the mutation (Tschammer et al, 2011). Fig 
8 shows the comparison of the wild type dopamine D2L receptor with a D2L H3936.35A 
receptor mutant through Log(max/EC50) and pEC50 values; it can be seen from 
this figure that, as with receptor selectivity and agonist bias, the effects of mutation are 
under-estimated if pEC50 values are utilized (as opposed to Log(max/EC50)).  
Quantifying PAM Effects 
An important distinction between negative allosteric modulators (NAMs) and 
positive allosteric modulators (PAMs) is that the effective affinity of the latter species 
(PAMs) depends much more on the co-binding ligand than does the former (NAMs). 
The reason for this comes from the expression for effective affinity of allosteric ligands 
in the Stockton-Ehlert allosteric binding model (Stockton et al, 1983; Ehlert, 1988). This 
predicts that the effective observed affinity of the allosteric modulator (expressed as  
Kobs) is given by: 
  …[3] 
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where KB is the equilibrium dissociation constant of the modulator-receptor 
complex with no co-binding ligand present and  is the effect of the modulator on the 
affinity of the co-binding ligand. It can be seen that for NAMs (where <<1), there will be 
a negative effect of co-binding ligand commensurate with standard antagonist 
experiments (i.e. basically a modified ‘Cheng-Prusoff’ (Cheng and Prusoff, 1973) 
relationship between observed and micro- affinity). However, in vivo, ambient agonist 
concentrations probably are not high and this modification of NAM potency will not be 
extensive. In contrast, for PAMs where >>1, it can be seen that the co-binding ligand 
will have a profound effect on the effective affinity of the modulator even for low 
concentrations of agonist. For a NAM with =0.01 and assuming a concentration of 
agonist = KA, the correction will be a factor of 1.1 whereas for a PAM with =100, the 
correction will be a 50-fold increase in observed affinity. This effect means that a useful 
estimation of the effective affinity of the PAM cannot be obtained in the absence of the 
co-binding ligand, a fact implicitly considered in the standard screening assay for PAMs. 
In these assays the PAM is added to an assay already partially activated by the 
endogenous agonist. When this is done the resulting potentiation of the endogenous 
agonist effect produces a sigmoidal concentration-response curve to the PAM referred 
to as an ‘R50’ curve-see Fig 9.  
An analysis of the midpoint and maximal asymptote of this curve yields an 
interesting parameter of PAM activity. Specifically, it can be seen that the parameter 
max/R50 (where R50 is EC50 of the R50 curve) of this curve (see fig 9) furnishes a 
parameter of agonist potentiation that, when used as a ratio, provides a system-
independent measure of the power of the PAMs involved to potentiate agonist 
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response- see Appendix 4 for derivation. Specifically, differences between Log(max/R50) 
values of R50 curves yield differences between the molecular system-independent 
parameters describing PAM, namely  and KB: 
Log(max/R50)  = Log(/KB)  …[4] 
This has the potential to be an extremely useful parameter since in theory it can 
be used to measure the relative effects of PAMs in vivo. This is important since the 
effective activity of PAMs is expressed only in the presence of the natural agonist and 
the effect of this is relatively unknown in vivo. However, through standard 
pharmacological null experimentation, R50 curves obtained in vivo can be used to 
compare PAMs in a system independent manner by simply comparing the effects of the 
PAMs on natural ambient agonist activity in the in vivo system. Fig 10 shows two 
Log(max/R50) curves for in vitro potentiation of muscarinic receptor activity of 
acetylcholine by two experimental PAMs (Mistry et al,2016). In this particular case, the 
Log(max/R50) values indicate comparable PAM effects; this is confirmed by individual 
estimation and calculation of Log(/KB) values measured from separate experiments 
fitting data to the functional allosteric model. Specifically, the Log(/KB) estimate for 
the compounds shown is 0.05 and the Log(max/R50) shows a comparable value 
(Log(max/R50)=0.12). This method is based on the null cancellation of the basal 
activity level of the system and the isolation of the effect of a PAM on that basal level of 
response.  
Conclusions 
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This paper proposes that two descriptive parameters for dose-response curves, 
namely the EC50 and maximal response, can be used to furnish system-independent 
ratios of agonist activity in a variety of settings. The inclusion of maximal response into 
the index for agonism takes into account the heterogeneous effects of varying system 
sensitivity on DR curves for partial and full agonists. This, in turn, allows seamless 
comparisons to be made between full and partial agonists in functional systems. The 
index, Log(max/EC50), embodies agonism into a single number which then lends itself to 
statistical analysis and allows null methods to cancel tissue effects such as receptor 
number, receptor coupling efficiency and amplification within functional assays between 
agonists for any given system. Once this cancellation has been done, Log(max/EC50) 
values become system-independent measures of the power of the test agonist(s) 
(compared to a reference agonist) to induce response in the defined system.  These 
indices then can be used to compare different systems; thus, Log(max/EC50) values 
can be used to quantify extracellular receptor selectivity, intracellular receptor selectivity 
(biased signaling), cell-specific agonism, and the effects of receptor mutation on natural 
signaling.  
In addition, the same parameters from a different type of dose-response curve, 
namely the potentiation of an ambient agonist response by a PAM, can be used to 
quantify allosteric modulation both in vitro and in vivo. This may be especially useful for 
the in vivo comparison of PAM effects since the affinity and potentiating activity of these 
types of molecules are dependent upon the presence of the co-binding ligand (in this 
case, the endogenous agonist) and this may be variable in vivo. However, if different 
PAMs are compared under similar conditions in an in vivo system, relative measures of 
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PAM activity based on molecular parameters of ligand-receptor interaction, may be 
derived.   
These approaches are clearly applicable to the advancement of candidate 
molecules in drug discovery programs (quantifying selectivity and bias). However, they 
also can be used to quantify molecular properties of receptors (differences in receptor 
signaling seen with receptor mutation) and even operational effects of different cell 
types on receptor signaling. This latter process could be especially useful in the 
optimization of cell type (i.e. pathology-related) agonism through medicinal chemistry. 
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Legends for Figures  
Fig 1. Effect of changing receptor density (and/or tissue sensitivity) on 
concentration response to a high efficacy agonist (Agonist1) and low Efficacy Agonist 
(Agonist2). A. Concentration response curves to Agonist1 (Solid line curves) and 
Agonist2 (dotted line curves) with increasing sensitivity of tissue. Note how less sinistral 
displacement of EC50 values for Agonist2 are observed vs that for Agonist1. B. 
Log(max/EC50) values (solid line) and pEC50 values (dotted line) with changing tissue 
sensitivity for Agonists 1 and 2. Note how pEC50 values vary with tissue sensitivity 
whereas Log(max/EC50) values remain stable 
Fig 2. Ratios of Log(max/EC50) values for the -adrenoceptor full agonist 
isoproterenol and the partial agonist prenalterol (Left ordinate axis; data as open circles) 
as a function of the maximal response to prenalterol in  range of isolated tissues 
(Abscissae). Dotted line shows the ratio of pEC50 values (Right ordinate axis; data in 
filled circles). Data from Kenakin and Beek (1982).  
Fig 3 Effects of efficacy (range of receptor densities)  and slope of the agonist 
concentration-response curve (Slope) on differences between indices of agonism as 
calculated by Log(/KA) vs Log(max/EC50) values.  
Fig 4.  Radar plot showing muscarinic receptor selectivity for four agonists 
activating M1 vs M4 receptors. Selectivity expressed as Log(max/EC50) values (solid 
line) and pEC50 values (dotted line). Data recalculated from Watt et al, 2011.  
Fig 5. Radar plot of receptor selectivity, compared to acetylcholine as a reference 
agonist, expressed as Log(max/EC50) values  (solid line) and pEC50 values (dotted 
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line) for 8 muscarinic agonists for agonism in guinea pig ileum and urinary bladder. Data 
from Ringdahl (1987). Column furthest to the right in the table indicates the maxima of 
agonists relative to that of acetylcholine- note how LogpEC50 values deviation from 
Log(max/EC50) increases with partial agonism.  
Fig 6  Radar plot showing biased signaling of -opioid agonists  (G proteins vs -
arrestin) either through Log(max/EC50) values (solid line) or pEC50 values (dotted  
line); reference agonist is salvinorin A. Data from White et al, 2012.  
Fig 7 Cell-based agonism: Bias plots showing relative responses to muscarinic agonists 
in HT-29 and SF268 cells. While the system bias for four of the agonists are relatively 
uniform, bethanechol stands out as being more active in SF268 cells than HT-29 cells. 
This effect can be quantified through a bias calculation as shown in the table below the 
figure. If the mean bias toward SF268 cells for acetylcholine, methacholine, Oxo-M and 
carbachol is 1.75, then bethanechol is 7.86/1.75= 4.5-fold selective for SF268 cells. 
Data from Deng et al, 2013. 
Fig 8 Effects of mutation on dopamine D2L receptor (comparison of wild type to D2L 
H3936.35A receptor) through a radar plot showing Log(max/EC50) values (solid line) or 
pEC50 values (broken line)- reference agonist is quinpirole. Data from Tschammer et 
al, 2011 .  
Fig 9 Potentiation of a sub-maximal agonist effect with 2 PAMs. Panel A shows the 
effects of PAM1 with  = 120 / = 0.8 / KB= 1 M; curves shown for control ([PAM1]=0) 
and 5 nM, 20 nM , 0.1 M, 0.5 M, 2 M and 10 M.   Panel C shows the effects of  
PAM2 =50 / = 3 / KB= 10 M; curves shown for control ([PAM2]=0) and 50 nM, 0.2 
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M, 1 M, 5 M, 20 M and 100 M. Panel B shows the dose-response curves for the 
PAMs (R50 curves) as potentiation of the agonist response. Log(max/EC50) value for 
PAM1 = 6.58 and Log(max/EC50) for PAM2 = 5.76 providing a  Log(max/EC50) value of  
0.82. From separate estimates of , , and KB used to construct the curves the value for 
Log(/KB) is 0.81.  
Fig 10. R50 curves for 2 PAMs for muscarinic  M1 receptors (filled circles = CMPD 10d / 
open circles CMPD 1). Table on right shows calculation of Log(max/R50) values (0.12); 
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                                                                                                      Table 1
                                                 Practical Application of the Log(max/EC50) Scale to Quantify Selectivity
Procedure Rationale
1.     Fit DR date to a function to yield max (maximal response) and EC50 
(concentration of agonist producing 50% maximal response to the agonist).
This furnishes individual values for Log(max/EC50), a single index of 
agonism
2.     Choose a reference agonist for comparison of all test agonists; use the 
same reference for all systems (receptors, pathways, cell types)
Ratios to the index for the reference aognist will allow cancellation 
of receptor denstiy, cell sensitivity, assay sensitivity differences
3.    Calculate log(max/EC50) values for each test agonist                                   
( LLog(max/EC50) = Log(max/EC50)ref - Log(max/EC50)test)
This will scale the agonist activity of the test agonist to the reference 
agonist within a given system (receptor type, signaling pathway, cell 
type etc)
4.  Calculate Log(max/EC50) values across the 2 systems being compared 
(different receptors, signaling pathways, cell types, receptor protein sequence)  
(Log(max/EC50) = Log(max/EC50)ref - Log(max/EC50)test)
With the individual differences in sensitivity between the two 
systems cancelled, Log(max/EC50) values provide a system 
independent measure of the relative agonism of each test agonist in 
both systems
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M1/M4 Receptor Selectivity for Agonists 
 
 
Data from Watt et al, 2011. 
  




                                                     Relative Agonism at M1 Receptors
Ach 1 25.7 7.59 7.59 0.00 1.000 0 1.000
Sabcomeline 0.389 56.2 6.84 7.25 -0.75 0.178 -0.34 0.457
Talsadidine 0.693 812.8 5.93 6.09 -1.66 0.022 -1.5 0.032
Xanolamine 0.637 43.7 7.16 7.36 -0.43 0.375 -0.23 0.589
                                                    Relative Agonism at M4 Receptors
Ach 0.87 52.5 7.22 7.28 0.00 1.000 0 1.000
Sabcomeline 0.2 67.6 6.47 7.17 -0.75 0.178 -0.11 0.776
Talsadidine 0.216 794.3 5.43 6.1 -1.79 0.016 -1.18 0.066
Xanolamine 0.46 63.1 6.86 7.2 -0.36 0.440 -0.08 0.832
Talsadidine selectivity calculated as Log(max/EC50)
Log(max/EC50)= 0.13 : Talsadidine is 10
0.13 = 1.38 selective for M1 receptors
Talsadidine selectivity calculated as pEC50
pEC50= -0.32: Talsadidine is 10
-0.32= 0.48 selective for M1 receptors 
     (2.1x selective for M4 receptors)
1 Relative Agonism based on Log(max/EC50) values
2 Relative Agonism based on EC50 values
This article has not been copyedited and formatted. The final version may differ from this version.




















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.


















This article has not been copyedited and formatted. The final version may differ from this version.
















Appendix 1. Agonism as a Positive Allosteric Modulation of Receptor-Signaling 
Protein Interaction 
The functional allosteric model (scheme 1) yields two receptor species that 
produce cellular response, namely [RG] and [ARG]. These interact with the cell stimulus 
response mechanisms: [RG] with an equilibrium dissociation constant KE to a signaling 
species [RGE] and [ARG] producing response with an equilibrium dissociation constant 
K’E to a signaling species [ARGE].  
From scheme 1 the system defines the following: 
  [RG] = [ARG]/[A]K’a   ……[5] 
  [AR] = [ARG]/[G]Kg  …..[6] 
  [R] = [ARG]/[A]K’a[G]Kg  …..[7] 
The receptor conservation equation ([Rtot] = [R] + [AR] + [RG] + [ARG]) can be re-written 
using equations 5 to 7 as: 
  [Rtot] = [G]/KG (1 + [A]/K’A) + [A]/K’A + 1   ….[8] 
where KG and K’A are equilibrium dissociation constants (K’A= 1/K’a and KG= 
1/Kg).  Substituting the term in equation 8 for [Rtot] and defining the fraction of receptors  
RG as G and ARG as AG respectively yields: 
  …[9] 
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The subsequent interaction of the receptor-signaling protein complex (either agonist 
bound or not) is processed through the Black/Leff operational model (Black and Leff, 
1983) as a forcing function to generate a response from the agonist. Specifically, these 
fractional receptor species can be entered into the Black/Leff operational model form for 
response: 
 …[11] 
The spontaneous active state receptor has a natural efficacy (denoted G) for the 
production of response through coupling to the signaling protein. Defining the efficacy of 
the active state receptor as G= [Rtot]/KE and the efficacy of the agonist-bound active 
state receptor as A = [Rtot]/KE’ further defines the factor  as the ratio of the efficacy of 
the non agonist-bound receptor (G) and agonist-bound receptor. The efficacy of the 
agonist in terms of the Black/Leff operational model (A) therefore yields the term  as 
A/G and  the operational model equation can be rewritten: 
 …[12] 
Substituting for G and AG from eqns 9 and 10 yields: 
 …[13] 
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Equation 13 defines a sigmoidal curve for the agonist results from which values of 
maximal response (denoted max) can be derived: 
 …[14] 
It should be noted that for all calculations utilizing the Black/Leff operational model and 
these indices of agonist activity, the maximal response to the agonist must be 
expressed as a fraction of the maximal window of response available in the assay. 
Thus, no agonist can produce a maximal response greater than unity (the maximal 
response window for the assay). Similarly, the  midpoint sensitivity of effect (denoted 
EC50) is given as: 
 …[15] 
Combining equations 14 and 15 yields: 
 …[16] 
It can be shown that a ratio of the quotients max/EC50 (where max refers to the maximal 
response to the agonist and the EC50 the concentration of agonist producing 50% of the 
agonist maximal response) results in a system independent parameter quantifying 
agonism. Utilized as  Log(max/EC50) values for two agonists (denoted agonist1 and 
agonist2), this can be shown to be: 
 Log(max/EC50)1-2  = Log(11/K’A-1) – Log(22/K’A-2)….[17] 
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Specifically, Equation 17 reveals that Log(max/EC50) is a combination of an assay and 
tissue term and a strictly agonist term (specifically /K’A): 
 …[18] 
Therefore, the ratio of max/EC50 values, which subtracts and thus cancels the two 
Log((G[G]/KGEm)/(G[G]/KG +1)) terms is independent of the assay and tissue effects 
and becomes a unique identifier of for the two agonists; for agonist1 and agonist2 
the Log(max/EC50) is Log(/K’A) which is a system independent ratio of agonism. 
The value /K’A is comprised of only drug parameters  ( is the change in the 
affinity of the receptor for the signaling protein produced by the binding of the agonist 
and reciprocally the affinity of the agonist when the signaling protein interacts with the 
receptor), K’A is the equilibrium dissociation of the receptor agonist complex when the 
receptor does not interact with the signaling protein  and  the change in the efficacy of 
the receptor for production of response produced by the agonist.  
Appendix 2. Relationship Between Log(max/EC50) and Log(/KA) Through the 
Black/Leff Operational Model 
Agonist response is modeled by the Black/Leff Operational model for systems 
yielding response with a variable Hill coefficient slope as (Black et al, 1985): 
    …[19] 
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where A is the efficacy of the agonist, n the Hill coefficient of the agonist 
concentration-response curve and Em the maximal response window of the functional 
assay. It should be noted that the K’A in equation 18 in terms of the Black/Leff model is 
the equilibrium dissociation constant of the agonist-response complex for agonism with 
the receptor interacting with the signaling protein. Therefore the KA term is the 
operational equilibrium dissociation constant of the agonist-receptor complex, i.e. 
agonist binding to the receptor as it interacts with the signaling protein. If the agonist is 
viewed as a modulator of signaling protein interaction then the operational KA is equal 
to/K’A. Black et al (1985) provided expressions for the maximal response (max) as: 
     …[20] 
And for the EC50 for half maximal response as: 
     …[21] 
This leads to an expression for max/EC50 of: 
    …..[22] 
For n=1, max/EC50=  Em/KA; ratios of (max/EC50) values cancel the tissue Em 
term and yield a strictly agonist-dependent term /KA. Therefore ratios of max/EC50 
values (in the form of Log(max/EC50) values for systems where the slope of the 
agonist concentration response curves is not significantly different form unity) yield 
strictly agonist dependent (and system-independent) values for relative agonism: 
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    …[23] 
Appendix 3. Statistical Assessment of Difference Using Log(max/EC50) Values 
If individual estimates of Log(max/EC50) are available, then a statistical estimate 
of mean Log(max/EC50) values, Log(max/EC50) values and Log(max/EC50) values 
can be calculated in the form of 95% confidence limits of the estimated values.  For a 
set of k to n values for agonist y activating signaling system j, sij2 is defined as: 
  [24] 
Values for sij2 are calculated for sets of K agonists and all signaling pathways to 
yield a pooled variance defined by: 
  …[25] 
Where dferror is given as: 
  ….[26] 
From these values, a 95% confidence limit with two-tailed T values (T97.5) can be 
calculated. For a mean Log(max/EC50) estimate: 
     …[27] 
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Within any one assay, agonist comparison to a standard yields a ratio of Log(max/EC50) 
values denoted as Log(max/EC50). The 95% c.l. of this ratio is defined as: 
 …[28] 
Once values have been normalized to a reference standard agonist within each group 
(receptor type, signaling pathway, cell type), then a 95% c.l. can be calculated for 
selectivity or bias for the Log(max/EC50) value as: 
 ….[29] 
The application of these formulae are depicted in the figure below.  
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Appendix 4. Application of Log(max/R50) values from R50 Curves to Quantify the 
Effects of PAMs 
The model for allosteric effects in functional systems defines agonist response as 
(Kenakin, 2005; Ehlert, 2005; Price et al, 2005): 
 …[30] 
where  is the effect of the modulator ([B]) on the affinity of the agonist for the 
receptor and  the effect of the modulator on the efficacy of the agonist. This equation 
can be rewritten in terms of the modulator as the active species to: 
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This defines the R50 curve for a potentiating modulator (PAM) increasing the 
effect of an ambient agonist response due to a presence of agonist acting on the 
receptor (in the form of [A]/KA).  
The maximal response of the R50 curve is thus given as: 
  …[32] 
And the half maximal effect of the R50 curve (defined as the R50) is given as: 
  …[33] 
This leads to the ratio of max/R50 as: 
     …[34] 
It can be seen that this expression is a mixture of tissue specific and agonist specific 
factors: 
  …[35] 
Therefore ratios of max/R50 values can provide system independent estimates of the 
relative activity of PAMs in potentiating agonist response: 
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Log(max/R50)A-B  =  Log(/KB)A – Log(/KB)B  …[36] 
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